Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K33/00 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/211792TREATMENT OF CORONAVIRUS INFECTIONS WITH AURANOFIN
WO 21.10.2021
Int.Class A61K 31/7135
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7135Compounds containing heavy metals
Appl.No PCT/US2021/027404 Applicant GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. Inventor KUMAR, Mukesh
The present disclosure provides methods for treating viral infections, in particular treating coronavirus infections in a subject with auranofin.
2.WO/2023/073086IRON OXIDE NANOPARTICLES WITH ANTIVIRAL ACTIVITY AGAINST SARS AND MERS CORONAVIRUS
WO 04.05.2023
Int.Class A61K 9/51
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
50Microcapsules
51Nanocapsules
Appl.No PCT/EP2022/080053 Applicant CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS Inventor BARBER CASTAÑO, Domingo F.
Coronaviridae viruses usually cause mild respiratory disease in humans, nevertheless a new infectious disease caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally since December 2019, resulting in the ongoing 2019 2021 coronavirus pandemic. The present invention discloses the use of coated iron oxide nanoparticles (IONPs) for use in the treatment and/or prevention of viral infections caused by Coronaviridae, especially those caused by respiratory syndrome-related coronaviruses such as SARS-CoV, SARS-CoV-2 and MERS-CoV. The iron oxide nanoparticles are coated with biocompatible molecules and polymers which bind to the nanoparticle core via oxygen, nitrogen and sulfur donor atoms (e.g. dextran, (3- aminopropyl)triethoxysilane or dimercaptosuccinic acid, respectively). The IONPs were found stable, non-cytotoxic in vitro and can efficiently impair virus replication, transcription and production of infectious virus. Furthermore, the IONPs are suitable for oral, intranasal or parenteral administration in combination with a pharmaceutical carrier.
3.WO/2023/073091IRON OXYHYDROXIDE NANOPARTICLES WITH ANTIVIRAL ACTIVITY AGAINST SARS AND MERS CORONAVIRUS
WO 04.05.2023
Int.Class A61K 33/26
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
26Iron; Compounds thereof
Appl.No PCT/EP2022/080059 Applicant CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS Inventor BARBER CASTAÑO, Domingo F.
Coronaviridae viruses usually cause mild respiratory disease in humans, nevertheless, a new infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally since December 2019, resulting in the ongoing 2019-2021 coronavirus pandemic. The present invention discloses the use of coated iron oxyhydroxide nanoparticles (lOHNPs) for use in the treatment and/or prevention of viral infections caused by Coronaviridae, especially those caused by respiratory syndrome-related coronaviruses such as SARS-CoV and SARS-CoV-2 and MERS-CoV. The iron oxyhydroxide nanoparticles are coated with biocompatible molecules and polymers which bind to the nanoparticle core via oxygen (e.g. sorbitol and sucrose). The lOHNPs were found stable, non-cytotoxic in vitro and can efficiently impair virus replication and transcription. Furthermore, the lOHNPs are suitable for oral, intranasal or parenteral administration in combination with a pharmaceutical carrier.
4.WO/2022/031416COMPOSITIONS AND METHODS FOR PREVENTION OF VIRAL INFECTIONS AND ASSOCIATED DISEASES
WO 10.02.2022
Int.Class A61K 33/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
20Elemental chlorine; Inorganic compounds releasing chlorine
Appl.No PCT/US2021/041682 Applicant MICROPURE, INC. Inventor JAIPRAKASH, Shewale, G.
Described herein are single-phase multi-component compositions and methods for their use reducing the viral load of infectious viruses on host organisms, including but not limited to Influenza A, Rhinovirus Type 14, Adenovirus Type 5, Herpes Simplex Virus Type 1, Herpes Simplex Virus Type 2, Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2; COVID-19 virus), Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), and Human coronavirus 229E. The compositions described herein comprise a combination of an oxidative compound and a buffering system. The methods of use of these compositions as antiviral agents when applied to the oral, nasal, ocular, aural, anal, and urogenital cavities are described. Data shows the compositions to be effective in reducing influenza A and the human coronaviruses. In that regard, the single-phase multi-component compositions and methods for its antiviral use disclosed herein may be offer a single, effective product to combat multiple, concurrent pandemics.
5.WO/2023/079466TREATMENT OF SEQUELAE OF CORONAVIRUS INFECTIONS
WO 11.05.2023
Int.Class A61K 33/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
04Sulfur, selenium or tellurium; Compounds thereof
Appl.No PCT/IB2022/060575 Applicant SULFAGENIX, INC. Inventor GOJON-ZORRILLA, Gabriel
The present invention features compositions and methods for treating sequelae of coronavirus infection, e.g., betacoronavirus. The present invention features a method of treating or preventing one or more sequelae of a coronavirus infection. The method includes administering to the subject a pharmaceutical composition including elemental alpha sulfur, highly polar components, and a pharmaceutically acceptable excipient in an amount and for a duration sufficient to treat or prevent the one or more sequelae of the coronavirus infection.
6.20220016053Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US 20.01.2022
Int.Class A61K 31/137
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines, e.g. amantadine
135having aromatic rings, e.g. methadone
137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
Appl.No 17357388 Applicant ZOGENIX INTERNATIONAL LIMITED Inventor Bradley S. Galer

Provided is a method of treating a patient infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), comprising: determining the patient has been infected with SARS-CoV-2; and administering to the patient a therapeutically effective dose of fenfluramine.

7.WO/2023/033753FOOD SUPPLEMENT WITH ANTIOXIDANT/ ANTIPROLIFERATIVE PROPERTIES
WO 09.03.2023
Int.Class A61K 36/282
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18Magnoliophyta (angiosperms)
185Magnoliopsida (dicotyledons)
28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
282Artemisia, e.g. wormwood or sagebrush
Appl.No PCT/TR2021/050883 Applicant ERDEM ÜNLÜ, Gülten Inventor ERDEM ÜNLÜ, Gülten
The present invention relates to a food supplement with antioxidant/antiproliferative properties that is used in the treatment of COVID-19 coronavirus disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), contains artemisia annua, distilled water, colloidal silver water and Olea Europaea (olive leaf oil extract).
8.WO/2023/056260METHODS, DEVICES, AND RELATED ASPECTS FOR DETECTING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2
WO 06.04.2023
Int.Class A61K 33/242
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
242Gold; Compounds thereof
Appl.No PCT/US2022/077110 Applicant ARIZONA BOARD OF REGENTS ON BEHALF OFARIZONA STATE UNIVERSITY Inventor WANG, Chao
Provided herein are methods of detecting severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in a sample. The methods include contacting the sample with a plurality of gold nanoparticles (AuNPs) and/or other plasmonic metal nanoparticles (MNPs) that are conjugated with at least two sets of antibodies, or antigen binding portions thereof, that binds to at least first and second epitopes of SARS-CoV-2 proteins, such as receptor-binding domain (RBDs) under conditions sufficient for the antibodies, or the antigen binding portions thereof, to bind to the first and second epitopes of the SARS-CoV-2 proteins in the sample to produce bound SARS-CoV-2 proteins. The methods also include detecting the SARS-CoV-2 proteins when aggregations of the bound SARS-CoV-2 proteins form with one another. Related compositions, reaction mixtures, devices, kits, and systems are also provided.
9.WO/2023/001814COMPOSITION FOR USE IN THE PREVENTION OF SEVERE FORMS OF VIRAL INFECTIONS DUE TO BETACORONAVIRUS
WO 26.01.2023
Int.Class A61K 31/155
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines, e.g. amantadine
155Amidines , e.g. guanidine , isourea , isothiourea
Appl.No PCT/EP2022/070184 Applicant CENTRE HOSPITALIER UNIVERSITAIRE DE NIMES Inventor CORBEAU, Pierre
The present invention concerns a composition comprising an Angiotensin receptor 1 (AT1) inhibitor and one or more other active compounds selected from the group consisting of antioxidants, caspase inhibitors, and mixtures thereof, for use as a drug in subjects in need thereof, for preventing and/or treating viral infections due to at least one betacoronavirus, in particular for preventing severe forms of viral infections due to betacoronavirus, in particular COVID-19 due to SARS-CoV-2.
10.WO/2021/207178SILVER NANOPARTICLES FOR USE IN INHIBITING AND TREATING CORONAVIRUS INFECTION
WO 14.10.2021
Int.Class A61K 9/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
08Solutions
Appl.No PCT/US2021/025942 Applicant AGARWAL, Ankit Inventor AGARWAL, Ankit
The present invention relates to the use of compositions comprising sialic acid to inhibit or treat coronavirus infections, and in particular those caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2).